JNJ

225.05

-1.11%↓

ABT

92.61

+1.53%↑

MDT

83.08

-0.36%↓

115.32

-0.08%↓

VEEV

161.12

+0.17%↑

JNJ

225.05

-1.11%↓

ABT

92.61

+1.53%↑

MDT

83.08

-0.36%↓

115.32

-0.08%↓

VEEV

161.12

+0.17%↑

JNJ

225.05

-1.11%↓

ABT

92.61

+1.53%↑

MDT

83.08

-0.36%↓

115.32

-0.08%↓

VEEV

161.12

+0.17%↑

JNJ

225.05

-1.11%↓

ABT

92.61

+1.53%↑

MDT

83.08

-0.36%↓

115.32

-0.08%↓

VEEV

161.12

+0.17%↑

JNJ

225.05

-1.11%↓

ABT

92.61

+1.53%↑

MDT

83.08

-0.36%↓

115.32

-0.08%↓

VEEV

161.12

+0.17%↑

Начало・Списък с акции・Puma Biotechnology Inc

Puma Biotechnology Inc

Отворен

СекторЗдравеопазване

7.45 -1.32

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

7.4

Максимум

7.68

Ключови измерители
By Trading Economics
Приходи	3M 12M
Продажби	21M 76M
P/E Средно за сектора	12.082 60.328
Марж на печалбата	15.633
Служители	179
EBITDA	13M 27M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	-33.69% downside

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	17M 375M
Предишно отваряне	8.77
Предишно затваряне	7.45

Настроения в новините

By Acuity

50%

141 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

3.07 / 3.075 Подкрепа & съпротива

Puma Biotechnology Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

26.04.2026 г., 21:14 ч. UTC

Значими събития в новините

Week Ahead for FX, Bonds: Major Central Bank Meetings Due as Middle East Conflict Continues

26.04.2026 г., 21:14 ч. UTC

Значими събития в новините

Week Ahead for FX, Bonds: Major Central Bank -2-

24.04.2026 г., 19:19 ч. UTC

Придобивния, сливания и поглъщания

Intertek Group Rejects EQT's Revised Offer

26.04.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise After U.S. Tech Gains -- Market Talk

26.04.2026 г., 23:44 ч. UTC

Печалби

Sinopharm 1Q Net CNY1.41B Vs. Net CNY1.46B >1099.HK

26.04.2026 г., 23:44 ч. UTC

Печалби

Sinopharm 1Q Rev CNY140.77B Vs. CNY141.66B >1099.HK

26.04.2026 г., 23:36 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Falls Amid Dollar's Strength -- Market Talk

26.04.2026 г., 23:33 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Rises Amid Ongoing Middle East Tensions -- Market Talk

26.04.2026 г., 05:12 ч. UTC

Печалби

Citic Securities: Results Also Aided by Higher Income from Brokerage, Income Banking Business >6030.HK

26.04.2026 г., 05:12 ч. UTC

Печалби

Citic Securities: Increase in Net Interest Income Supported Results >6030.HK

26.04.2026 г., 05:12 ч. UTC

Печалби

Citic Securities 1Q Rev CNY23.16B Vs. CNY16.43B >6030.HK

26.04.2026 г., 05:12 ч. UTC

Печалби

Citic Securities 1Q Net CNY10.22B Vs. Net CNY6.61B >6030.HK

24.04.2026 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Scoring the Cook Era -- Barrons.com

24.04.2026 г., 20:51 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Financial Services Roundup: Market Talk

24.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

24.04.2026 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 20:09 ч. UTC

Печалби

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24.04.2026 г., 19:48 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24.04.2026 г., 19:25 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 19:25 ч. UTC

Придобивния, сливания и поглъщания

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24.04.2026 г., 19:22 ч. UTC

Печалби

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24.04.2026 г., 19:06 ч. UTC

Печалби

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24.04.2026 г., 19:05 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24.04.2026 г., 18:30 ч. UTC

Придобивния, сливания и поглъщания

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24.04.2026 г., 18:28 ч. UTC

Придобивния, сливания и поглъщания

Intertek Rejects Revised EQT Offer

24.04.2026 г., 18:12 ч. UTC

Пазарно говорене

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24.04.2026 г., 18:06 ч. UTC

Пазарно говорене

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24.04.2026 г., 17:42 ч. UTC

Печалби

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24.04.2026 г., 17:28 ч. UTC

Печалби

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Puma Biotechnology Inc Прогноза

Ценова цел

By TipRanks

-33.69% надолу

12-месечна прогноза

Среден 5 USD -33.69%

Висок 5 USD

Нисък 5 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Puma Biotechnology Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Puma Biotechnology Inc през последните 3 месеца.

Техническа оценка

By Trading Central

3.07 / 3.075Подкрепа & съпротива

Recent bullish events outweigh bearish events.

Настроение

By Acuity

141 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.